Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy

Launched by MEDICAL UNIVERSITY OF VIENNA · Dec 28, 2016

Keywords

ClinConnect Summary

The group B Streptococcus (GBS) or Streptococcus agalactiae is a gram-positive bacterium that is present in 10-30% of the healthy female population (1). Throughout pregnancy and the intrapartum period, maternal colonization with GBS can lead to the vertical transmission of the bacterium to the infant. This can result in neonatal sepsis, pneumonia, and meningitis, known as early-onset GBS infection, as well as in maternal urinary tract infections, arthritis, and pneumonia (2). Various strategies were tested to prevent the GBS infection. The antenatal GBS screening was successfully proven to ...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women btw. 34 + 0 and 36 + 0 gestational weeks
• • GBS positive at GBS screening (study visit 1)
• • No current vaginal infection (i.e., Nugent score 0-6 w/o other pathogens at study visit 1)
• Exclusion Criteria:
• • Multiple pregnancy
• • Vaginal bleeding
• • Current vaginal infection (i.e., bacterial vaginosis, chlamydia, trichomoniasis, candidiasis or others)
• • Antibiotics \< 4 weeks to randomization
• • Probiotics \< 4 weeks to randomization